Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Astellas...
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)
In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Astellas Pharma, with a price target of Yen1,600.00. The company’s shares closed last Friday at $11.10.Elevate Your Investing...
Why Shares of Adaptive Biotechnologies Jumped This Week
The company could see its first FDA-approved therapy as early as next year.